OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sutro Biopharma OCF Yield % Related Terms
Sutro Biopharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:S090 vs CCCC, OCGN, FULC: OCF Yield % Comparison
For the Biotechnology subindustry, Sutro Biopharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (STU:S090) has a OCF Yield % of -30.47 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #1085 out of 1419 companies in the Biotechnology industry, placing it in the top 76.5%.
Is Sutro Biopharma's OCF Yield % too high?
Sutro Biopharma's current OCF Yield % is -30.47. Based on the distribution chart, Sutro Biopharma ranks #1085 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sutro Biopharma has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's OCF Yield % compare to CCCC and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #1085 out of 1419 companies for OCF Yield %. This places Sutro Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current OCF Yield % is -30.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Sutro Biopharma (STU:S090) has a current OCF Yield % of -30.47. The stock's GF Value™ is €2.66, compared to a current price of €6.24 — trading 134.4% above its estimated fair value. The current OCF Yield % is -30.47. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Sutro Biopharma (STU:S090), the current OCF Yield % is -30.47 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STU:S090) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of €6.24 is trading 134.4% above its estimated GF Value™ of €2.66.
Key valuation signals for STU:S090:
OCF Yield %: -30.47
GF Value™: €2.66 vs. price of €6.24 (134.4% above fair value)
No single metric tells the full story. See the STU:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STU:S090
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S090 has been successfully added to your 
